Efficacy of the early administration of valacyclovir hydrochloride for the treatment of neuropathogenic equine herpesvirus type-1 infection in horses.

OBJECTIVE To determine whether prophylactic administration of valacyclovir hydrochloride versus initiation of treatment at the onset of fever would differentially protect horses from viral replication and clinical disease attributable to equine herpesvirus type-1 (EHV-1) infection. ANIMALS 18 aged mares. PROCEDURES Horses were randomly assigned to receive an oral placebo (control), treatment at detection of fever, or prophylactic treatment (initiated 1 day prior to viral challenge) and then inoculated intranasally with a neuropathogenic strain of EHV-1. Placebo or valacyclovir was administered orally for 7 or 14 days after EHV-1 inoculation or detection of fever (3 horses/group). Effects of treatment on viral replication and clinical disease were evaluated. Plasma acyclovir concentrations and viremia were assessed to determine inhibitory concentrations of valacyclovir. RESULTS Valacyclovir administration decreased shedding of virus and viremia, compared with findings for control horses. Rectal temperatures and clinical disease scores in horses that received valacyclovir prophylactically for 2 weeks were lower than those in control horses. The severity of but not the risk for ataxia was decreased by valacyclovir administration. Viremia was decreased when steady-state trough plasma acyclovir concentrations were > 0.8 μg/mL, supporting the time-dependent activity of acyclovir. CONCLUSIONS AND CLINICAL RELEVANCE Valacyclovir treatment significantly decreased viral replication and signs of disease in EHV-1-infected horses; effects were greatest when treatment was initiated before viral inoculation, but treatment was also effective when initiated as late as 2 days after inoculation. During an outbreak of equine herpesvirus myeloencephalopathy, antiviral treatment may be initiated in horses at various stages of infection, including horses that have not yet developed signs of viral disease.

[1]  M. Payton,et al.  Papiine herpesvirus 2 as a predictive model for drug sensitivity of Macacine herpesvirus 1 (monkey B virus). , 2014, Comparative medicine.

[2]  P. Jadhav,et al.  From in vitro EC50 to in vivo dose–response for antiretrovirals using an HIV disease model. Part II: Application to drug development , 2012, Journal of Pharmacokinetics and Pharmacodynamics.

[3]  W. D. Wilson,et al.  Prevalence of equine herpesvirus type 1 in trigeminal ganglia and submandibular lymph nodes of equids examined postmortem , 2010, Veterinary Record.

[4]  S. Hussey,et al.  Control of EHV-1 viremia and nasal shedding by commercial vaccines. , 2010, Vaccine.

[5]  Kentaro Kato,et al.  Characterization of a thymidine kinase-deficient mutant of equine herpesvirus 4 and in vitro susceptibility of the virus to antiviral agents. , 2010, Antiviral research.

[6]  H. Nauwynck,et al.  Evaluation of orally administered valacyclovir in experimentally EHV1-infected ponies. , 2009, Veterinary microbiology.

[7]  G. Allen.  Risk factors for development of neurologic disease after experimental exposure to equine herpesvirus-1 in horses. , 2008, American journal of veterinary research.

[8]  R. S. Erkert,et al.  Pharmacokinetics of valacyclovir in the adult horse. , 2008, Journal of veterinary pharmacology and therapeutics.

[9]  W. D. Wilson,et al.  Diagnostic sensitivity of nasopharyngeal and nasal swabs for the molecular detection of ehv-1 , 2008, Veterinary Record.

[10]  H. Nauwynck,et al.  Pharmacokinetics of Acyclovir after Intravenous Infusion of Acyclovir and after Oral Administration of Acyclovir and Its Prodrug Valacyclovir in Healthy Adult Horses , 2007, Antimicrobial Agents and Chemotherapy.

[11]  H. Nauwynck,et al.  In vitro susceptibility of six isolates of equine herpesvirus 1 to acyclovir, ganciclovir, cidofovir, adefovir, PMEDAP and foscarnet. , 2007, Veterinary microbiology.

[12]  G. Allen,et al.  Outbreak of neurologic disease caused by equine herpesvirus-1 at a university equestrian center. , 2007, Journal of veterinary internal medicine.

[13]  G. Allen,et al.  Quantification by real-time PCR of the magnitude and duration of leucocyte-associated viraemia in horses infected with neuropathogenic vs. non-neuropathogenic strains of EHV-1. , 2010, Equine veterinary journal.

[14]  W. D. Wilson,et al.  Cytokine gene signatures in neural tissue of horses with equine protozoal myeloencephalitis or equine herpes type 1 myeloencephalopathy , 2006, Veterinary Record.

[15]  C. van Maanen,et al.  Equine herpesvirus type 1-associated myeloencephalopathy in The Netherlands: a four-year retrospective study (1999-2003). , 2006, Journal of veterinary internal medicine.

[16]  G. Reubel,et al.  A type-specific serological test to distinguish antibodies to equine herpesviruses 4 and 1 , 2005, Archives of Virology.

[17]  K. Smith,et al.  In vitro characterisation of high and low virulence isolates of equine herpesvirus-1 and -4. , 2003, Research in veterinary science.

[18]  J. Kydd,et al.  Clinical and virological evaluation of the efficacy of an inactivated EHV1 and EHV4 whole virus vaccine (Duvaxyn EHV1,4). Vaccination/challenge experiments in foals and pregnant mares. , 2001, Vaccine.

[19]  F. Lokiec,et al.  Pharmacokinetics of Oral Acyclovir in Neonates and in Infants: a Population Analysis , 2001, Antimicrobial Agents and Chemotherapy.

[20]  D. Bernstein,et al.  A temporal analysis of acyclovir inhibition of induced herpes simplex virus type 1 In vivo reactivation in the mouse trigeminal ganglia. , 1999, The Journal of infectious diseases.

[21]  R. Fujinami,et al.  Replacement of Loop II of VP1 of the DA Strain with Loop II of the GDVII Strain of Theiler’s Murine Encephalomyelitis Virus Alters Neurovirulence, Viral Persistence, and Demyelination , 1998, Journal of Virology.

[22]  R. Eberle,et al.  Shedding and transmission of baboon Herpesvirus papio 2 (HVP2) in a breeding colony. , 1998, Laboratory animal science.

[23]  E. Dubovi,et al.  Neonatal equine herpesvirus type 1 infection on a thoroughbred breeding farm. , 1998, Journal of veterinary internal medicine.

[24]  D. Dorman,et al.  Effects of valacyclovir in cats infected with feline herpesvirus 1. , 1997, American journal of veterinary research.

[25]  A. Awan,et al.  The acyclic nucleoside analogue penciclovir is a potent inhibitor of equine herpesvirus type 1 (EHV-1) in tissue culture and in a murine model. , 1992, Antiviral research.

[26]  D. Sutton,et al.  Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture , 1987, Antimicrobial Agents and Chemotherapy.

[27]  E. Rollinson.  Comparative efficacy of three 2'-fluoropyrimidine nucleosides and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (BW B759U) against pseudorabies and equine rhinopneumonitis virus infection in vitro and in laboratory animals. , 1987, Antiviral research.

[28]  J. Balzarini,et al.  A novel selective broad-spectrum anti-DNA virus agent , 1986, Nature.

[29]  E. Rollinson,et al.  Relative activities of acyclovir and BW759 against Aujeszky's disease and equine rhinopneumonitis viruses. , 1983, Antimicrobial Agents and Chemotherapy.

[30]  K. K. Ogilvie,et al.  Sensitivity of equine herpesviruses 1 and 3 in vitro to a new nucleoside analogue, 9-[[2-hydroxy-1-(hydroxymethyl) ethoxy] methyl] guanine. , 1983, American journal of veterinary research.

[31]  R. Whitlock,et al.  Spinal cord disease in the horse. , 1978, The Cornell veterinarian.